$161 Million is the total value of INTERNATIONAL BIOTECHNOLOGY TRUST PLC's 45 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 35.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INCY | Buy | Incyte Corp | $12,705,000 | +19.9% | 254,500 | +27.2% | 7.88% | +56.6% |
| VRTX | Buy | Vertex Pharmaceuticals Inc | $11,726,000 | +17.2% | 90,122 | +33.1% | 7.28% | +53.0% |
| CELG | Sell | Celgene Corp | $11,361,000 | -34.7% | 225,522 | -11.0% | 7.05% | -14.7% |
| GILD | Buy | Gilead Sciences Inc | $10,482,000 | +96.1% | 213,284 | +136.2% | 6.50% | +156.0% |
| REGN | Regeneron Pharmaceuticals | $9,189,000 | -5.3% | 31,330 | 0.0% | 5.70% | +23.6% | |
| EXEL | Sell | Exelixis Inc | $9,105,000 | -4.9% | 589,534 | -16.3% | 5.65% | +24.2% |
| ILMN | Sell | ILLUMINA INC | $7,915,000 | -45.5% | 33,600 | -34.9% | 4.91% | -28.8% |
| NBIX | Buy | Neurocrine Biosciences Inc | $7,053,000 | +110.7% | 125,800 | +254.4% | 4.38% | +175.1% |
| BMRN | Sell | Biomarin Pharmaceutical Inc | $6,175,000 | -14.6% | 92,284 | -5.1% | 3.83% | +11.5% |
| LGND | Buy | Ligand Pharmaceuticals Inc | $5,998,000 | -18.5% | 56,300 | +60.9% | 3.72% | +6.4% |
| ALXN | Sell | Alexion Pharmaceuticals Inc | $5,632,000 | -35.3% | 73,641 | -9.8% | 3.50% | -15.5% |
| KALV | Sell | Kalvista Pharmaceuticals Inc | $4,954,000 | -9.4% | 319,444 | -0.9% | 3.07% | +18.3% |
| HALO | Sell | Halozyme Therapeutics Inc | $4,579,000 | -23.3% | 398,633 | -7.0% | 2.84% | +0.2% |
| STML | Stemline Therapeutics Inc | $4,366,000 | -41.5% | 585,930 | 0.0% | 2.71% | -23.6% | |
| BIIB | New | Biogen Inc | $4,062,000 | – | 17,200 | +100.0% | 2.52% | – |
| AMGN | New | Amgen Inc | $3,670,000 | – | 24,000 | +100.0% | 2.28% | – |
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $3,579,000 | +245.8% | 282,065 | +333.9% | 2.22% | +351.4% |
| RDUS | Buy | Radius Health Inc | $3,419,000 | +1230.4% | 264,211 | +1305.5% | 2.12% | +1639.3% |
| SHPG | Shire plcsponsored adr | $3,418,000 | -1.6% | 25,000 | 0.0% | 2.12% | +28.4% | |
| ABMD | Sell | Abiomed Inc | $2,987,000 | -34.4% | 11,700 | -11.4% | 1.85% | -14.3% |
| ZGNX | Sell | Zogenix Inc | $2,659,000 | -36.4% | 93,000 | -15.5% | 1.65% | -17.0% |
| ENTA | New | Enanta Pharmaceuticals Inc | $2,390,000 | – | 43,000 | +100.0% | 1.48% | – |
| XENT | Sell | Intersect Ent Inc | $2,123,000 | -14.0% | 96,000 | -14.3% | 1.32% | +12.3% |
| ALNY | Sell | Alnylam Pharmaceuticals Inc | $1,935,000 | -45.4% | 33,800 | -36.0% | 1.20% | -28.7% |
| SGEN | Seattle Genetics Inc | $1,890,000 | -24.8% | 42,500 | 0.0% | 1.17% | -1.8% | |
| IONS | Sell | Ionis Pharmaceuticals Inc | $1,698,000 | -16.6% | 40,000 | -22.3% | 1.05% | +8.9% |
| NKTR | New | NEKTAR THERAPEUTICS | $1,548,000 | – | 60,000 | +100.0% | 0.96% | – |
| SRPT | Sell | Sarepta Therapeutics Inc | $1,457,000 | -56.4% | 17,000 | -37.0% | 0.90% | -43.1% |
| BLUE | Bluebird Bio Inc | $1,324,000 | -30.4% | 17,000 | 0.0% | 0.82% | -9.1% | |
| AGIO | Agios Pharmaceuticals Inc | $1,321,000 | -38.8% | 36,500 | 0.0% | 0.82% | -20.1% | |
| SAGE | Sage Therapeutics Inc | $1,203,000 | -30.5% | 15,996 | 0.0% | 0.75% | -9.2% | |
| HZNP | Horizon Pharma Plc | $1,059,000 | +2.2% | 69,000 | 0.0% | 0.66% | +33.5% | |
| STRO | SUTRO BIOPHARMA INC | $1,052,000 | -37.6% | 146,653 | 0.0% | 0.65% | -18.5% | |
| AMRN | New | Amarin Corp Plcspons adr new | $854,000 | – | 80,000 | +100.0% | 0.53% | – |
| GMED | Sell | Globus Med Inc | $822,000 | -34.9% | 24,200 | -16.6% | 0.51% | -15.0% |
| ARRY | Sell | Array Biopharma Inc | $811,000 | -91.8% | 72,500 | -91.4% | 0.50% | -89.2% |
| GWPH | GW Pharmaceuticals Plcads | $732,000 | -42.5% | 9,600 | 0.0% | 0.45% | -25.0% | |
| FGEN | Sell | FibroGen Inc | $716,000 | -51.1% | 19,700 | -37.3% | 0.44% | -36.2% |
| SBPH | Spring Bk Pharmaceuticals Inc | $596,000 | -11.4% | 73,000 | 0.0% | 0.37% | +15.6% | |
| SUPN | Supernus Pharmaceuticals Inc | $547,000 | -32.4% | 20,953 | 0.0% | 0.34% | -11.7% | |
| FOLD | Amicus Therapeutics Inc | $440,000 | -19.0% | 58,600 | 0.0% | 0.27% | +5.8% | |
| SGMO | Sell | Sangamo Therapeutics Inc | $432,000 | -70.5% | 48,000 | -57.5% | 0.27% | -61.5% |
| AERI | Sell | Aerie Pharmaceuticals Inc | $425,000 | -92.8% | 15,000 | -88.0% | 0.26% | -90.6% |
| ONCE | Spark Therapeutics Inc | $369,000 | -26.5% | 12,000 | 0.0% | 0.23% | -4.2% | |
| PTLA | New | PORTOLA PHARMACEUTICALS INC | $367,000 | – | 24,000 | +100.0% | 0.23% | – |
| RSLS | Exit | ReShape Lifesciences Inc | $0 | – | -52,546 | -100.0% | -0.00% | – |
| CRVS | Exit | Corvus Pharmaceuticals Inc | $0 | – | -108,000 | -100.0% | -0.34% | – |
| PRTK | Exit | Paratek Pharmaceuticals Inc | $0 | – | -103,500 | -100.0% | -0.36% | – |
| MRUS | Exit | Merus N V | $0 | – | -75,060 | -100.0% | -0.54% | – |
| CBAY | Exit | Cymabay Therapeutics Inc | $0 | – | -145,000 | -100.0% | -0.58% | – |
| MDGL | Exit | Madrigal Pharmaceuticals Inc | $0 | – | -10,000 | -100.0% | -0.78% | – |
| DCPH | Exit | Deciphera Pharmaceuticals Inc | $0 | – | -77,000 | -100.0% | -1.09% | – |
| JAZZ | Exit | Jazz Pharmaceuticals PLC | $0 | – | -21,600 | -100.0% | -1.32% | – |
| GTHX | Exit | G1 Therapeutics Inc | $0 | – | -72,000 | -100.0% | -1.37% | – |
| SPPI | Exit | Spectrum Pharmaceuticals Inc | $0 | – | -300,000 | -100.0% | -1.84% | – |
| PBYI | Exit | Puma Biotechnology Inc | $0 | – | -144,300 | -100.0% | -2.41% | – |
| ADMS | Exit | Adamas Pharmaceuticals Inc | $0 | – | -370,000 | -100.0% | -2.70% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GILEAD SCIENCES INC COMMO | 28 | Q3 2023 | 9.3% |
| INCYTE CORP INC COM | 28 | Q3 2023 | 7.9% |
| BIOMARIN PHARMACEUTICALS INC | 28 | Q3 2023 | 7.5% |
| REGENERON PHARMS. | 27 | Q3 2023 | 9.0% |
| BIOGEN INC COMMON STOCK | 26 | Q3 2023 | 8.7% |
| VERTEX PHARMS. | 25 | Q3 2023 | 8.4% |
| AMGEN INC COM | 25 | Q3 2023 | 7.9% |
| NEUROCRINE BIOSCIENCES INC | 25 | Q3 2023 | 6.9% |
| ALYNYLAM PHARMACEUTICALS INC | 25 | Q3 2023 | 6.7% |
| IONIS PHARMS. | 25 | Q3 2023 | 4.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Altus Pharmaceuticals Inc. | February 12, 2009 | ? | ? |
| MICROMET, INC. | February 14, 2008 | 1,907,390 | 4.7% |
| EPIMMUNE INC | February 15, 2005 | 1,279,659 | 8.0% |
| ESSENTIAL THERAPEUTICS INC | April 29, 2003 | 2,500,000 | 11.7% |
| TARGETED GENETICS CORP /WA/ | April 18, 2003 | ? | ? |
| ESSENTIAL THERAPEUTICS INC | November 05, 2001 | 11 | 13.0% |
| ONYX PHARMACEUTICALS INC | October 15, 2001 | 11 | 13.0% |
| CORVAS INTERNATIONAL INC | October 12, 2001 | 11 | 13.0% |
| RIBOZYME PHARMACEUTICALS INC | October 05, 2001 | 11 | 13.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-18 |
| 13F-HR | 2023-02-01 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-20 |
| 13F-HR | 2022-02-15 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.